Accordingly, we evaluated the populations of circulating stem cells (CD133+) and early EPCs (CD133+/VEGFR2+) in AIS patients, in addition to the functional, chemotactic effect of ACEIs on circulating EPCs in these patients, taking into account aforementioned aspects of stroke pathogenesis. This evidence concerns the gene PROM1 and Stroke.